CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Health, formerly known as Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, has announced a rebrand to reflect the company’s success in utilizing artificial intelligence (AI) to strengthen clinical research and augment clinical decision making within gastroenterology.
In this new chapter, Iterative Health will continue to focus on its core products, AI Recruitment, SKOUT™, and AI Documentation. AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease (IBD) clinical trials. Recruiting qualified patients is one of the most significant and expensive challenges of clinical trials, but AI-R helps determine if patients are qualified for clinical trials by providing support for gastroenterologists and their research staff.
SKOUT, a real-time computer-aided polyp detection device with FDA 510(k) clearance, uses advanced computer vision technology designed to recognize suspicious tissue during colorectal cancer screening and surveillance. SKOUT significantly improves overall adenoma detection compared to standard colonoscopy. In its registration trial, published in Gastroenterology, SKOUT demonstrated a 27% relative increase in the detection of adenomas per colonoscopy.1
Lastly, AI Documentation, which is currently in development, may soon have the power to provide detailed and accurate procedure documentation. This will allow gastroenterologists to review evidence-based documentation, rather than create it from scratch. This product will be co-developed and marketed with Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions.
The company’s new name, Iterative Health, emphasizes its commitment to advancing precision medicine and continuing to raise the bar for both accuracy and consistency in physician decision-making. Iterative Health is standardizing high-quality care through AI-enhanced approaches while keeping the health of patients at the heart of its mission.
“Iterative Health is the next evolution for our team,” said Jonathan Ng, founder and CEO of Iterative Health. “While we will not stray from our roots, this rebrand highlights our mission to create a scalable, more equitable approach to GI care. Our application of advanced machine learning and computer vision is wide-reaching and will ultimately bring better diagnostics and health outcomes for patients. We believe our brand reinforces our commitment to establishing a new standard of care for patients through AI technology.”
Today not only marks the launch of a new brand, but a new website and visual identity as well. To learn more about Iterative Health visit iterative.health.
About Iterative Health
Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colonoscopy screenings. We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI related diseases.
Iterative Health is initially applying these advances towards standardizing disease severity characterization for inflammatory bowel disease. Ultimately, the company aims to establish more meaningful endpoints to serve as better predictors of both therapeutic response and disease outcomes. The company is based in Cambridge, Massachusetts.
1Shaukat A, Lichtenstein D, Somers S, et al. (2022). Computer-Aided Detection Improves Adenomas per Colonoscopy for Screening and Surveillance Colonoscopy: A Randomized Trial. Gastroenterology.
